|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500105854 |
|
最近更新日期: Date of Last Refreshed on: |
2025-07-14 09:14:14 |
|
注册时间: Date of Registration: |
2025-07-14 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
探讨胸腔镜肺切除术中医用粘合剂使用有效性和安全性的多中心、 前瞻性、随机对照研究 |
|
Public title: |
To explore the effectiveness and safety of medical adhesives used in thoracoscopic lung resection:a multicenter, prospective, randomized controlled study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
探讨胸腔镜肺切除术中医用粘合剂使用有效性和安全性的多中心、 前瞻性、随机对照研究 |
|
Scientific title: |
To explore the effectiveness and safety of medical adhesives used in thoracoscopic lung resection:a multicenter, prospective, randomized controlled study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吴鑫春 |
研究负责人: |
乔坤 |
|
Applicant: |
Wu Xinchun |
Study leader: |
Qiao Kun |
|
申请注册联系人电话: Applicant telephone: |
+86 133 5299 8996 |
研究负责人电话: Study leader's telephone: |
+86 180 2538 8707 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
281953964@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
szqiaokun@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
深圳市龙岗区布澜路29号 |
研究负责人通讯地址: |
深圳市龙岗区布澜路29号 |
|
Applicant address: |
No. 29, Bulan Road, Longgang District, Shenzhen |
Study leader's address: |
No. 29, Bulan Road, Longgang District, Shenzhen |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
深圳市第三人民医院 |
||
|
Applicant's institution: |
Shenzhen Third People's Hospital |
||
|
研究负责人所在单位: |
深圳市第三人民医院 |
||
|
Affiliation of the Leader: |
Shenzhen Third People's Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
深圳三院伦审科研字[2024-207-02]号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
深圳市第三人民医院科研伦理委员会 |
||
|
Name of the ethic committee: |
Scientific Research Ethics Committee of Shenzhen Third People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-10-08 00:00:00 |
||
|
伦理委员会联系人: |
韩雨 |
||
|
Contact Name of the ethic committee: |
HANYU |
||
|
伦理委员会联系地址: |
深圳市龙岗区布澜路29号 |
||
|
Contact Address of the ethic committee: |
No. 29, Bulan Road, Longgang District, Shenzhen |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 755 6122 2333 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
深圳市第三人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shenzhen Third People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
深圳市龙岗区布澜路29号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 29, Bulan Road, Longgang District, Shenzhen |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
企业资助 |
||||||||||||||||||||||
|
Source(s) of funding: |
Corporate sponsor |
||||||||||||||||||||||
|
Target disease: |
pulmonary nodule |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究受试者选择采用拟行胸腔镜肺楔形切除的患者。符合入排标准后按照随机1:1分组,试验组使用医用粘合剂封闭切缘和肺组织创面;对照组不使用医用粘合剂,术后两组均留置1根猪尾巴引流管。通过观察术后并发症的发生率,以此评价医用粘合剂使用的有效性和安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
The subjects in this study selected patients who are scheduled to undergo thoracoscopic pulmonary wedge resection. After meeting the inclusion criteria, patients are randomly divided into each group (Experimental group or Control group). The experimental group use medical adhesive to seal the resection margin and lung tissue wounds; the control group does not use such medical adhesive, and a pig tail drainage tube is left in both groups after surgery. The effectiveness and safety of medical adhesives are evaluated by observing the incidence of postoperative complications. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.80岁>=年龄>=18 岁,性别不限; 2.术前诊断为胸部CT发现的肺部最大直径<=2cm且CTR<=0.25的混合型GGO或纯GGO; 3.结节位于肺外周1/3带,拟行胸腔镜肺楔形切除术者; 4.患者知情同意,并自愿签署“受试者知情同意书” |
||||||||||||||||||||||
|
Inclusion criteria |
1.80 years old >= age>=18 years old, gender is not limited; 2. Preoperative diagnosis is mixed GGO or pure GGO with maximum lung diameter <=2cm and CTR <=0.25 found on chest CT; 3. Pumornary nodules located in the peripheral 1/3 of the lung, who are to undergo thoracoscopic lung wedge resection; 4. The patient gave informed consent and voluntarily sign the "Subject Informed Consent Form" |
||||||||||||||||||||||
|
排除标准: |
1.术中行系统性纵隔淋巴结清扫; 2.术中中转开胸; 3.胸膜粘连严重者; 4.伴有严重的凝血功能异常者; 5.重度慢性阻塞性肺病、肺气肿患者; 6.严重心、肺、肝、肾等脏器的基础疾病; 7.预期寿命小于12个月者; 8.正处于妊娠期或哺乳期、处于生命危急情况的患者; 9.1个月内参加过其他任何临床试验的患者; 10.术前已行肺部抗肿瘤治疗(放疗、消融、靶向、免疫、化学治疗)的患者 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Performing systematic mediastinal lymph node dissection during surgery; 2. Convert to thoracotomy during operation; 3. Those with severe pleural adhesion; 4. Those with severe coagulation abnormalities; 5. Patients with severe chronic obstructive pulmonary disease and emphysema; 6. Severe basic diseases of the heart, lungs, liver, kidneys and other organs; 7. Those whose life expectancy is less than 12 months; 8. Patients who are pregnant or lactating and in a life-critical situation; 9. Patients who have participated in any other clinical trials within 1 month; 10. Patients who have received lung anti-tumor treatment (radiotherapy, ablation, targeted, immunotherapy, chemotherapy) before surgery |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-10-15 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-11-14 00:00:00 至 To 2024-11-14 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由统计学专家采用专业统计软件产生随机分配序列,即随机号及对应组别 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Statistical experts use professional statistical software to generate a random allocation sequence, that is, random numbers and corresponding groups, and |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
单盲 |
|
Blinding: |
single blind |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2027年1月1日跟主中心研究发起者乔坤联系邮箱:szqiaokun@163.com |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Contact Qiao Kun, the PI of this research |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |